Skip to main content
رجوع
HKMPY logo

Hikma Pharmaceuticals PLC

جودة البيانات: 100%
HKMPY
OTC Healthcare Drug Manufacturers - Specialty & Generic
KWD 32.98
▼ KWD 1.15 (-3.36%)
القيمة السوقية: 3.63B
مُدرج أيضًا باسم HKMPF OTC
نطاق اليوم
KWD 32.98 KWD 34.88
نطاق 52 أسبوعًا
KWD 31.80 KWD 56.94
حجم التداول
550
متوسط 50 يوم / 200 يوم
KWD 39.84 / KWD 45.96
الإغلاق السابق
KWD 34.13

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E 9.0 0.4
P/B 1.4 2.9
ROE % 16.4 3.7
Net Margin % 12.0 3.8
Rev Growth 5Y % 7.1 10.0
D/E 0.6 0.2

النقاط الرئيسية

Revenue grew 7.08% annually over 5 years — modest growth
ROE of 16.44% — decent returns on equity
Generating 162.38M in free cash flow
P/E of 9.01 — trading at a low valuation
PEG of 0.89 suggests growth is underpriced
Capital efficient — spends only 5.88% of revenue on capex

النمو

Revenue Growth (5Y)
7.08%
Revenue (1Y)7.35%
Earnings (1Y)12.24%
FCF Growth (3Y)-36.60%

الجودة

Return on Equity
16.44%
ROIC11.06%
Net Margin12.00%
Op. Margin18.63%

الأمان

Debt / Equity
0.64
Current Ratio1.82
Interest Coverage5.89

التقييم

P/E Ratio
9.01
P/B Ratio1.40
EV/EBITDA7.92
Dividend Yield0.04%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 7.35% Revenue Growth (3Y) 8.06%
Earnings Growth (1Y) 12.24% Earnings Growth (3Y) 45.63%
Revenue Growth (5Y) 7.08% Earnings Growth (5Y) -1.09%
Profitability
Revenue (TTM) 3.36B Net Income (TTM) 402.94M
ROE 16.44% ROA 7.11%
Gross Margin 40.04% Operating Margin 18.63%
Net Margin 12.00% Free Cash Flow (TTM) 162.38M
ROIC 11.06% FCF Growth (3Y) -36.60%
Safety
Debt / Equity 0.64 Current Ratio 1.82
Interest Coverage 5.89 Dividend Yield 0.04%
Valuation
P/E Ratio 9.01 P/B Ratio 1.40
P/S Ratio 1.08 PEG Ratio 0.89
EV/EBITDA 7.92 Dividend Yield 0.04%
Market Cap 3.63B Enterprise Value 4.95B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3.36B 3.13B 2.88B 2.52B 2.55B
Net Income 402.94M 359.00M 190.00M 188.00M 421.00M
EPS (Diluted) 3.62 3.22 1.72 1.68 3.62
Gross Profit 1.34B 1.42B 1.41B 1.24B 1.30B
Operating Income 625.46M 612.00M 367.00M 282.00M 582.00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 5.67B 5.13B 4.68B 4.47B 4.37B
Total Liabilities 3.07B 2.81B 2.47B 2.32B 1.91B
Shareholders' Equity 2.59B 2.31B 2.20B 2.14B 2.45B
Total Debt 1.65B 1.31B 1.19B 1.28B 846.00M
Cash & Equivalents 328.00M 188.00M 205.00M 270.00M 426.00M
Current Assets 2.64B 2.26B 2.10B 2.00B 2.09B
Current Liabilities 1.45B 1.98B 1.34B 1.08B 1.02B

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#349 of 658
27

النشاط الأخير

دخل Contrarian Investing (David Dreman)
Mar 24, 2026